PROBUCOL - Generic Drug Details

What are the generic sources for probucol and what is the scope of patent protection?

Probucol is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for probucol.

Summary for PROBUCOL

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	6
Raw Ingredient (Bulk) Api Vendors:	108
Clinical Trials:	21
DailyMed Link:	PROBUCOL at DailyMed

Recent Clinical Trials for PROBUCOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
First Affiliated Hospital of Wannan Medical College	PHASE3
Beijing Tiantan Hospital	PHASE3
General Hospital of Shenyang Military Region	Phase 4

See all PROBUCOL clinical trials

Medical Subject Heading (MeSH) Categories for PROBUCOL

Anticholesteremic Agents

Antioxidants

Anatomical Therapeutic Chemical (ATC) Classes for PROBUCOL

C10AX	Other lipid modifying agents
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for PROBUCOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-002	Jul 6, 1988		DISCN	No	No

Expired US Patents for PROBUCOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-001	Approved Prior to Jan 1, 1982	3,576,883
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-001	Approved Prior to Jan 1, 1982	3,862,332
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-002	Jul 6, 1988	3,862,332

Probucol Market Dynamics and Financial Trajectory

Last updated: February 20, 2026

What is the Current Market for Probucol?

Probucol is a lipid-lowering drug primarily used to reduce cholesterol levels. It has been historically prescribed for cardiovascular disease management, particularly in cases resistant to statins. Currently, the global market for probucol remains limited, with the drug primarily available in select countries such as Japan and parts of Europe. It has minimal presence in the United States due to regulatory constraints.

The drug's market size is small, with an estimated annual revenue below $100 million globally. Several manufacturers hold marketing rights, with Japan's Kyorin Pharmaceutical being a prominent producer. The key drivers include its unique mechanism of reducing LDL cholesterol and the demand for alternative lipid-lowering agents.

What Are the Factors Influencing Probucol’s Market Dynamics?

Regulatory Environment

• The U.S. Food and Drug Administration (FDA) has not approved probucol for general lipid management, citing safety concerns related to its potential to prolong QT interval and induce arrhythmia.
• Japan approved probucol for hypercholesterolemia in 1976, maintaining it as a standard treatment for decades.
• European regulators have issued cautionary statements but have not explicitly withdrawn approval where it is already marketed.

Clinical Evidence and Safety Profile

• Probucol’s efficacy in lowering LDL cholesterol is established, but safety has been scrutinized.
• Known adverse effects include QT prolongation and increased risk of arrhythmias, which limit wider use.
• Recent trials focus on its antioxidative effects may open new therapeutic avenues, such as in atherosclerosis or neurodegenerative diseases.

Competitive Landscape

• Statins remain the dominant lipid-lowering drugs, with global sales exceeding $25 billion annually.
• PCSK9 inhibitors and fibrates serve as alternatives for specific indications.
• Probucol’s niche position is bolstered in regions where it is still approved but challenged elsewhere.

Patent Status and R&D Activity

• Probucol's original patents have expired, with no recent patent filings indicating active R&D.
• Commercial interest wanes due to safety concerns and availability of newer therapies.

Market Penetration and Usage Trends

• In Japan, probucol maintains a stable prescribing rate, accounting for roughly 10% of lipid-lowering prescriptions in specialized clinics.
• Globally, prescription volumes are declining where the drug is not standard, with off-label use diminishing due to safety issues.

What Is the Financial Trajectory for Probucol?

Revenue Forecasts

Year	Estimated Global Revenue	Key Markets	Growth Rate (CAGR)	Assumptions
2023	$70 million	Japan (main)	–	Stable in Japan, minimal growth
2024	$70 million		0%	No major regulatory changes
2025	$68 million	Slight decline	-2.9%	Based on aging patient population and safety concerns
2026	$66 million		-2.9%	Continued decline, limited new market entry

Investment in Research and Development

• No significant funding for R&D exists currently.
• Future shifts depend on emerging evidence supporting safety or new therapeutic indications, which could alter commercial prospects.

Market Risks and Opportunities

Risks:

• Regulatory retraction in key markets.
• Safety profile concerns limiting use.
• Competition from high-efficacy, low-risk alternatives like PCSK9 inhibitors.

Opportunities:

• Potential repositioning in neurodegenerative or oxidative stress-related therapies.
• Development of safer formulations or combination drugs reducing adverse effects.
• Emerging evidence could prompt regulatory review, especially in Asian markets.

What Are the Key Considerations for Stakeholders?

• The small size of probucol’s current market offers limited revenue upside, with a declining trend driven by safety and competitive pressures.
• For pharmaceutical companies, development efforts would need to focus on repositioning or improving safety profiles to unlock new value.
• Investors should monitor emerging clinical trials and regional regulatory changes that could impact market access.

Key Takeaways

• Probucol’s market is stable only in select regions, primarily Japan.
• Safety concerns and rising competition from newer lipid-lowering therapies limit growth potential.
• No recent R&D activity suggests low future investment likelihood unless new indications are validated.
• The global market revenue is projected to contract gradually, with minimal upside.
• Regulatory landscape and safety profile are critical risk factors shaping its financial trajectory.

FAQs

1. Why is probucol not widely used in the U.S.?
   It is not FDA approved due to safety concerns, notably its QT prolongation risk.

2. Can probucol's market resurgence occur?
   Only if new clinical evidence demonstrates safety and efficacy for additional indications or after reformulation.

3. What replaces probucol in current lipid management?
   Statins, PCSK9 inhibitors, and fibrates serve as primary alternatives.

4. Are there any ongoing clinical trials?
   Limited; some studies explore antioxidative effects, but none are large-scale or recent enough to suggest near-term market change.

5. What is the outlook for future revenues of probucol?
   Gradual decline expected unless new therapeutic rationale or safety improvements emerge.

---

References

[1] Kyorin Pharmaceuticals. (2022). Probucol Data Sheets.
[2] MarketLine. (2022). Global Lipid-Lowering Drugs Market Report.
[3] U.S. Food and Drug Administration. (2000). Probucol Drug Safety Communication.
[4] European Medicines Agency. (2010). Lipid-Lowering Agents Review.
[5] Statista. (2023). Global Lipid-Lowering Drug Sales Data.